Anti-tumorigenic mechanisms mediated by the tumor suppressor p53, upon oncogenic
stresses, are our bodies' greatest weapons to battle against cancer onset and development …

Despite tremendous progress in the past decade, the complex and heterogeneous nature of
cancer complicates efforts to identify new therapies and therapeutic combinations that …

The clinical relevance of comprehensive molecular analysis in rare cancers is not
established. We analyzed the molecular profiles and clinical outcomes of 1,310 patients …

Pediatric solid and central nervous system tumors are the leading cause of cancer-related
death among children. Identifying new targeted therapies necessitates the use of pediatric …

Cell lines are key tools for preclinical cancer research, but it remains unclear how well they
represent patient tumor samples. Direct comparisons of tumor and cell line transcriptional …

Cancer dependency maps have accelerated the discovery of tumor vulnerabilities that can
be exploited as drug targets when translatable to patients. The Cancer Genome Atlas …

The efficacy of current antimitotic cancer drugs is limited by toxicity in highly proliferative
healthy tissues. A cancer-specific dependency on the microtubule motor protein KIF18A …

Genomic analyses have revealed mutational footprints associated with DNA maintenance
gone awry, or with mutagen exposures. Because cancer therapeutics often target DNA …

Despite advances in precision medicine, the clinical prospects for patients with ovarian and
uterine cancers have not substantially improved. Here, we analyzed genome-scale CRISPR …

Integrating diverse types of biological data is essential for a holistic understanding of cancer
biology, yet it remains challenging due to data heterogeneity, complexity, and sparsity …